After Plunging -19.13% in 4 Weeks, Here's Why the Trend Might Reverse for Amarin (AMRN)Zacks Investment Research • 11/19/24
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual European Association for the Study of Diabetes (EASD) MeetingGlobeNewsWire • 09/09/24
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) CongressGlobeNewsWire • 08/22/24
Amarin Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 07/31/24
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in PortugalGlobeNewsWire • 07/17/24
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024GlobeNewsWire • 07/17/24
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)GlobeNewsWire • 07/08/24
LA BOUTIQUE Opens Flagship Store at Gaysorn Amarin: The New Must-Visit Destination in BangkokGlobeNewsWire • 06/07/24
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.GlobeNewsWire • 05/28/24
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/06/24
Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular EventGlobeNewsWire • 04/24/24
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024GlobeNewsWire • 04/15/24
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24GlobeNewsWire • 04/08/24